1. Home
  2. MDWD vs MPAA Comparison

MDWD vs MPAA Comparison

Compare MDWD & MPAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • MPAA
  • Stock Information
  • Founded
  • MDWD 2000
  • MPAA 1968
  • Country
  • MDWD Israel
  • MPAA United States
  • Employees
  • MDWD N/A
  • MPAA N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • MPAA Auto Parts:O.E.M.
  • Sector
  • MDWD Health Care
  • MPAA Consumer Discretionary
  • Exchange
  • MDWD Nasdaq
  • MPAA Nasdaq
  • Market Cap
  • MDWD 208.2M
  • MPAA 188.9M
  • IPO Year
  • MDWD 2014
  • MPAA 1994
  • Fundamental
  • Price
  • MDWD $20.52
  • MPAA $11.78
  • Analyst Decision
  • MDWD Strong Buy
  • MPAA
  • Analyst Count
  • MDWD 2
  • MPAA 0
  • Target Price
  • MDWD $35.00
  • MPAA N/A
  • AVG Volume (30 Days)
  • MDWD 48.8K
  • MPAA 310.9K
  • Earning Date
  • MDWD 08-13-2025
  • MPAA 08-07-2025
  • Dividend Yield
  • MDWD N/A
  • MPAA N/A
  • EPS Growth
  • MDWD N/A
  • MPAA N/A
  • EPS
  • MDWD N/A
  • MPAA N/A
  • Revenue
  • MDWD $19,213,000.00
  • MPAA $757,354,000.00
  • Revenue This Year
  • MDWD $20.80
  • MPAA $7.74
  • Revenue Next Year
  • MDWD $26.92
  • MPAA $5.00
  • P/E Ratio
  • MDWD N/A
  • MPAA N/A
  • Revenue Growth
  • MDWD N/A
  • MPAA 5.53
  • 52 Week Low
  • MDWD $14.14
  • MPAA $5.16
  • 52 Week High
  • MDWD $22.51
  • MPAA $12.72
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 50.69
  • MPAA 67.01
  • Support Level
  • MDWD $19.07
  • MPAA $11.86
  • Resistance Level
  • MDWD $19.55
  • MPAA $12.60
  • Average True Range (ATR)
  • MDWD 0.56
  • MPAA 0.58
  • MACD
  • MDWD -0.03
  • MPAA 0.23
  • Stochastic Oscillator
  • MDWD 88.89
  • MPAA 95.87

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About MPAA Motorcar Parts of America Inc.

Motorcar Parts of America Inc is a supplier of automotive aftermarket non-discretionary replacement parts and test solutions and diagnostic equipment. It operate in the non-discretionary automotive aftermarket for replacement hard part in North America and includes products such as light-duty rotating electrical products, wheel hub products, brake-related products, and turbochargers. In addition, it sell test solutions and diagnostic equipment. The company operates in three segments Hard Parts, Test Solutions and Diagnostic Equipment, and Heavy Duty. Key revenue is generated from Hard Parts, which includes (i) light duty rotating electric products such as alternators and starters, (ii) wheel hub products, (iii) brake-related products, including brake calipers, brake boosters, brake rotors.

Share on Social Networks: